Erica Mayer

28PUBLICATIONS
214CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsHealth informatics and information systemsChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Oct 14, 2025
Oncology's ongoing struggle with evaluating quality of life limiting, treatment-related toxicity.

Seamus O'Reilly, Siobhan Gaynor, Erica L Mayer

|Aug 25, 2025
Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study.

Lorenzo Gerratana, Carolina Reduzzi, Yue Ren

|Jun 02, 2025
First-Line Camizestrant for Emerging <i>ESR1</i>-Mutated Advanced Breast Cancer.

François-Clément Bidard, Erica L Mayer, Yeon Hee Park

|Feb 06, 2025
Patient preferences for CDK4/6 inhibitor treatments in HR+/HER2- early breast cancer: a discrete choice survey study.

Erica L Mayer, Mary Lou Smith, Annie Guérin

|Oct 09, 2024
Further Optimizing Care of Patients With Operable Hormone Receptor-Sensitive Breast Cancer.

Alexandra Thomas, Erica L Mayer, Angela DeMichele

|Sep 03, 2024
A Phase II Study of Atezolizumab, Pertuzumab, and High-Dose Trastuzumab for Central Nervous System Metastases in Patients with HER2-Positive Breast Cancer.

Antonio Giordano, Priya U Kumthekar, Qingchun Jin

Pageof 5

Frequent Collaborators

8 joint publications

Angela M DeMichele

7 joint publications

Sara Tolaney

7 joint publications

Antonio C Wolff

6 joint publications

Eric P Winer